Auriga Establishes Scientific Advisory Board of World-Renowned Scientists in Medical and Pharmaceutical Industries

Share Article

Board members have collectively published hundreds of clinical papers and filed over 70 patents.

Auriga Pharmaceuticals, LLC,, a specialty pharmaceutical company led by a team of noted scientists and industry executives, has established a Scientific Advisory Board to counsel the company in its drug development initiatives. Auriga currently markets and sells the Extendryl® line of cough, cold, and allergy products to select physician specialties and has several drugs in the development stage.

Glynn Wilson, Ph.D., Auriga’s chief scientific officer, serves as the board’s chairman. Four globally recognized scientists with deep expertise in the development of new pharmaceutical products and drug delivery technologies have joined the board to offer expertise in the areas of drug delivery, clinical trial design, patient selection, and FDA interaction. With the board’s founding, Auriga has created a structure for these scientists to advise in the company’s current development projects, as well as to help guide new avenues of research and product offerings.

“With the initiation of our scientific advisory committee, Auriga has taken another important step to become a world-class pharmaceutical organization,” said Philip S. Pesin, chairman and CEO of Auriga. “These scientists will meet regularly with our senior management team to help initiate new development projects, evaluate current projects, and suggest other avenues of discovery. Their collective medical research and pharmaceutical industry experience is extraordinary, and these scientists can provide unprecedented insight into new drug delivery mechanisms and other ways we can offer value in health care."

The board is composed of the following individuals:

  •     Glynn Wilson, Ph.D., is a recognized leader in the development of drug delivery systems with extensive experience in such technologies. Dr. Wilson was worldwide leader of drug delivery at SmithKline Beecham Pharmaceuticals where he was involved in the development of products involving new drug delivery systems. In addition, he was a founding member of the Advanced Drug Delivery Group at Ciba-Geigy Pharmaceuticals. As executive vice president for research and development at Tacora Corporation, he was responsible for conceiving and developing lead products, currently in clinical trials, and providing leadership for the merging of Tacora Corporation with Access Pharmaceuticals.
  •     Lisbeth Illum, Ph.D., D.Sc., has earned international acclaim as a researcher who has published more than 300 scientific papers, co-edited four books, and filed more than 30 patent applications on novel drug delivery systems. Her research has focused on novel drug delivery systems for peptide and protein drugs, primarily using transmucosal routes. In addition, her work has established fundamental concepts in the area of colloidal carrier systems for site-specific delivery of drugs. Dr. Illum is currently a director of Identity, a drug delivery consultancy. She earlier founded and was a managing director of DanBioSyst UK, Ltd, which was acquired by West Pharmaceutical Services where she subsequently became managing director and chief scientist at the company’s Drug Delivery and Clinical Center in Nottingham, U.K. Dr. Illum has held a number of academic positions at the Royal Danish School of Pharmacy, Copenhagen, and in the Pharmacy Department, University of Nottingham U.K. Dr. Illum earned her MPharm, Ph.D., and D.Sc. from the Royal Danish School of Pharmacy, Copenhagen.
  •     Kenneth Klein, M.D., is a Harvard-trained physician who is board-certified in both internal medicine and gastroenterology. He is currently president of Endpoint, which provides expertise on the clinical development of medicines to multinational pharmaceutical companies, emerging biomedical ventures, contract research organizations, regulatory agencies, and national health services. In his 15 years at Wellcome and Glaxo Wellcome, Dr. Klein took major products from Phase I through regulatory approval and marketing. He was global project leader for the anti-migraine drug zolmitriptan, marketed as Zomig®, and led all aspects of the drug's worldwide development. Dr. Klein earlier was on the GI faculties of the medical schools at Oregon Health Sciences University, Stanford University, and the University of North Carolina. He earned an A.B. in Chemistry from Harvard College and an M.D. from Harvard Medical School.
  •     James W. McGinity, Ph.D., is an internationally renowned researcher in the areas of physical pharmacy and pharmaceutical technology. He currently is professor and division head of pharmaceutics in the College of Pharmacy, The University of Texas at Austin, where he holds the Johnson and Johnson Centennial Chair in Pharmacy. Prior to his university appointment in 1976, he was a research scientist in the pharmaceutical industry at the Squibb Institute for Medical Research. Dr. McGinity’s research emphasis has been on novel drug delivery systems, including solid dosage forms, microencapsulation, powder technology, transdermal systems, and hot-melt extrusion. He has been issued 23 U.S. patents and currently has many others in review. He received a B.Pharm. degree from the University of Queensland, Brisbane, Australia, and a Ph.D. in Physical Pharmacy from the University of Iowa.
  •     John Staniforth, Ph.D., FRSC, has a distinguished career in both pharmaceutical research and the development of drug delivery technologies, having published more than 200 scientific papers and been an inventor on 45 patents.. He is currently chief scientific officer and a founder of Vectura Group plc, a specialty pharmaceuticals company that develops inhaled pharmaceutical products using novel drug delivery technologies, and an honorary visiting professor in the Department of Pharmacy, University of Bath, U.K. Prior to joining Vectura, he was on the University of Bath faculty. He is the inventor or co-inventor of several commercialized drug delivery systems, including TIMERx® for Penwest Pharmaceuticals Inc. as well as drug delivery technologies under development by PharmaKodex Ltd. Dr. Staniforth is a non-executive director of Penwest and was a founding director of Phoqus Pharmaceuticals Group plc, a U.K. company formed to commercialize his xerographic tablet-coating invention. He earned a BSc in Pharmacy and a Ph.D. in Pharmaceutical Technology from Aston University, U.K.

About Auriga Pharmaceuticals, LLC

Auriga Pharmaceuticals, LLC, a wholly-owned subsidiary of Auriga Laboratories, Inc., develops and markets new prescription products for approved drugs using proprietary drug delivery technologies and reformulation strategies. The specialty pharmaceutical company has a development division and a commercialization division, both based in Norcross, Georgia. A highly integrated team of experienced pharmaceutical executives manages product life cycle from development through marketing and sales. The company currently markets Extendryl®, a line of prescription cough/cold medications. More information is available at the company’s website at:

Contact Information:

Philip Pesin


# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Philip Pesin

Email >
Visit website